Oxford BioMedica (LSE: OXB), a leading gene therapy company, reported today that encouraging data from five Phase II studies of TroVax, its lead cancer immunotherapy product, were presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO). In addition, the Company provided an update on the clinical development plan for TroVax, which is progressing towards the start of Phase III trials in renal and colorectal cancer.
